Improving telehealth delivery of cancer care at home
Official title: MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
Run by Memorial Sloan Kettering Cancer Center · NCT06954337 · Data updated 2026-11-12
This study is testing if using telehealth can make cancer care at home better for patients with breast and prostate cancer, so they don’t have to go to the hospital as often.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1750 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | March 1, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT06954337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with breast or prostate cancer who have had at least three prior medical oncology visits at Memorial Sloan Kettering Cancer Center.
✕Probably not a fit
Patients currently enrolled in a therapeutic clinical trial or those whose primary language is not supported by the telehealth system will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to enhance the delivery of cancer care for patients with breast and prostate cancer by utilizing telehealth services, reducing the need for in-person visits. Conducted at Memorial Sloan Kettering Cancer Center, the study will involve patients who have had multiple prior oncology visits and will assess the effectiveness and safety of this telehealth approach. The trial will implement both physician and patient measures to evaluate outcomes and patient satisfaction with remote care.
Why it matters
Potential benefit: If successful, this approach could significantly improve access to cancer care for patients, making it more convenient and less burdensome.
How similar studies have gone: Other studies have shown promising results in utilizing telehealth for cancer care, indicating that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Center who have had at least 3 prior medical oncology visits. Exclusion Criteria: * Patient is enrolled on a therapeutic clinical trial. * Patients whose primary language is not currently supported by Epic.
Where it's running
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States Recruiting
Show 1 more location
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York, United States Recruiting
Study contacts
- Principal investigator: Erin Bange, MD, MSCE — Memorial Sloan Kettering Cancer Center
- Study coordinator: Erin Bange, MD, MSCE
- Email: bangee@mskcc.org
- Phone: 646-422-4680
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted radiopharmaceuticals for GRPR-positive cancers in adults
A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.
-
HER2 FPBMC therapy for metastatic breast and prostate cancer
This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
OCT-598 for advanced solid tumors
This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.